BioCryst Pharma (BCRX) Misses Q4 EPS by 23c

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), $0.23 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $79.5 million versus the consensus estimate of $75.57 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• ScanSource (SCSC) Tops Q4 EPS by 32c